These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29061479)

  • 41. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
    Jiménez-Alonso J; Tercedor J; Jáimez L; García-Lora E
    Arthritis Rheum; 1998 Apr; 41(4):744-5. PubMed ID: 9550488
    [No Abstract]   [Full Text] [Related]  

  • 42. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial.
    Kuhn A; Gensch K; Haust M; Schneider SW; Bonsmann G; Gaebelein-Wissing N; Lehmann P; Wons A; Reitmeir P; Ruland V; Luger TA; Ruzicka T
    J Am Acad Dermatol; 2011 Jul; 65(1):54-64, 64.e1-2. PubMed ID: 21501887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rosacea-like cutaneous lupus erythematosus: an atypical presentation responding to antimalarials.
    Marzano AV; Lazzari R; Polloni I; Boneschi V; Crosti C
    Acta Derm Venereol; 2013 Jan; 93(1):106-7. PubMed ID: 23053047
    [No Abstract]   [Full Text] [Related]  

  • 44. [Eye toxicity of antimalarial agents].
    Graña Gil J; Cabana Vázquez M; Vázquez González A; Sánchez Meizoso MO
    An Med Interna; 2002 Apr; 19(4):189-91. PubMed ID: 12090061
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review.
    Shipman WD; Vernice NA; Demetres M; Jorizzo JL
    J Am Acad Dermatol; 2020 Mar; 82(3):709-722. PubMed ID: 31306730
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus.
    Geraminejad P; Stone MS; Sontheimer RD
    Lupus; 2004; 13(6):473-7. PubMed ID: 15303576
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dapsone as Second-Line Treatment for Cutaneous Lupus Erythematosus? A Retrospective Analysis of 34 Patients and a Review of the Literature.
    Klebes M; Wutte N; Aberer E
    Dermatology; 2016; 232(1):91-6. PubMed ID: 26606129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.
    Zeidi M; Kim HJ; Werth VP
    J Invest Dermatol; 2019 Feb; 139(2):324-332. PubMed ID: 30227141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fatal antimalarial-induced cardiomyopathy: report of 2 cases.
    Azimian M; Gultekin SH; Hata JL; Atkinson JB; Ely KA; Fuchs HA; Mobley BC
    J Clin Rheumatol; 2012 Oct; 18(7):363-6. PubMed ID: 23047537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cutaneous lupus erythematosus: update of therapeutic options part I.
    Kuhn A; Ruland V; Bonsmann G
    J Am Acad Dermatol; 2011 Dec; 65(6):e179-93. PubMed ID: 20739095
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.
    Kishi C; Motegi SI; Yasuda M; Ishikawa O
    J Dermatol; 2018 Aug; 45(8):1020-1022. PubMed ID: 30133802
    [No Abstract]   [Full Text] [Related]  

  • 52. [Antimalarial's retinopaty remains a current threat].
    Chiffoleau A; Guillet A; Zanlonghi X; Jolliet P
    Presse Med; 2009 Apr; 38(4):662-3. PubMed ID: 19135848
    [No Abstract]   [Full Text] [Related]  

  • 53. Patients opinion and adherence to antimalarials in lupus erythematosus and rheumatoid arthritis treatment.
    Cabral RTS; Klumb EM; Carneiro S
    J Dermatolog Treat; 2020 May; 31(3):264-269. PubMed ID: 30935255
    [No Abstract]   [Full Text] [Related]  

  • 54. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
    Parke A; West B
    J Rheumatol; 1996 Oct; 23(10):1715-8. PubMed ID: 8895146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus.
    Avgerinou G; Papafragkaki DK; Nasiopoulou A; Arapaki A; Katsambas A; Stavropoulos PG
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):762-7. PubMed ID: 21707772
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of whole blood hydroxychloroquine concentration with cutaneous lupus erythematosus and factors associated with it: First multicenter, cross-sectional analysis in Malaysia.
    Peh D; Wan Ahmad Kammal WSL; Beh PJ; Yong ACH; Tan WC; Lim AL; Thevarajah S; Stanslas J; How KN
    J Dermatol; 2022 May; 49(5):545-549. PubMed ID: 35067938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment.
    Jewell ML; McCauliffe DP
    J Am Acad Dermatol; 2000 Jun; 42(6):983-7. PubMed ID: 10827400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidemiological characteristics of patients with cutaneous lupus erythematosus.
    Avilés Izquierdo JA; Cano Martínez N; Lázaro Ochaita P
    Actas Dermosifiliogr; 2014; 105(1):69-73. PubMed ID: 24268922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.
    Zeidi M; Chen KL; Patel J; Desai K; Kim HJ; Chakka S; Lim R; Werth VP
    Lupus; 2022 Apr; 31(4):472-481. PubMed ID: 35258358
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.